Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.88 USD | +6.64% | +7.81% | +42.47% |
May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.47% | 6.32B | |
+47.81% | 54.63B | |
-5.52% | 39.92B | |
+36.98% | 38.82B | |
+14.96% | 26.86B | |
-12.56% | 26.22B | |
-21.76% | 18.78B | |
+26.94% | 12.21B | |
+1.43% | 12.16B | |
+28.23% | 11.94B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Oppenheimer Adjusts Revolution Medicines Price Target to $35 From $30, Maintains Outperform Rating